List view / Grid view
25 June 2014 | By Merck
If approved, fixed-dose combination would be used with other antiretroviral agents for the treatment of HIV-1 in adults, adolescents and certain pediatric patients...
25 June 2014 | By Johnson & Johnson
Johnson & Johnson Innovation, Boston and Janssen Biotech, Inc. announced a three-year immuno-oncology lung cancer collaboration with the Dana-Farber Cancer Institute...
25 June 2014 | By Merck
Merck announced the future appointment of Michael J. Holston as general counsel, effective July 01, 2015...
25 June 2014 | By Bristol-Myers Squibb
Bristol-Myers Squibb Company announced that a randomized blinded comparative Phase 3 study evaluating nivolumab versus dacarbazine in patients with previously untreated BRAF wild-type advanced melanoma was stopped early...
24 June 2014 | By Abbott
Abbott announced a definitive agreement to acquire Veropharm, a leading Russian pharmaceutical manufacturer...
23 June 2014 | By Johnson & Johnson
Johnson & Johnson announced that its Board of Directors has appointed D. Scott Davis, Chief Executive Officer and Chairman of United Parcel Service, Inc. as a Director of Johnson & Johnson...
23 June 2014 | By Pfizer
Adults 65 or older can now be immunized with the same Pneumococcal Conjugate Vaccine used in children...
23 June 2014 | By Merck
Merck is commencing, through a subsidiary, a cash tender offer to purchase all outstanding shares of common stock of Idenix Pharmaceuticals, Inc...
23 June 2014 | By AbbVie
The board of directors of AbbVie Inc. declared a quarterly cash dividend of $0.42 per share...
23 June 2014 | By Novo Nordisk
New data from the phase 3a SCALE™ Diabetes trial were presented at the International Congress of Endocrinology and the Endocrine Society’s meeting, investigating the effect of liraglutide 3 mg in adults...
23 June 2014 | By Boehringer Ingelheim
Boehringer Ingelheim announces a new study of Pradaxa® (dabigatran etexilate) in patients with atrial fibrillation...
19 June 2014 | By Sanofi
Sanofi announced that, in a pooled analysis, investigational therapy Toujeo® (insulin glargine [rDNA origin] injection, 300 U/mL) consistently showed significantly fewer low blood sugar events (hypoglycemia)...
19 June 2014 | By Pfizer
Pfizer Inc. and Cellectis announced that they have entered into a global strategic collaboration to develop Chimeric Antigen Receptor T-cell (CAR-T) immunotherapies in the field of oncology directed at select targets...
19 June 2014 | By Johnson & Johnson
Janssen Pharmaceuticals, Inc. announced that it has entered into an exclusive license agreement with Vertex Pharmaceuticals...
19 June 2014 | By H. Lundbeck A/S
Lundbeck will present results about sexual functioning from a head-to-head study of Brintellix® (vortioxetine) vs. escitalopram in patients with well treated Major Depressive Disorder...
